Stockreport

Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024

Verona Pharma plc - American Depositary Shares  (VRNA) 
US:NASDAQ Investor Relations: nasdaq.com/symbol/vrna/real-time
PDF PDUFA Target Action Date of June 26, 2024 Eight posters including two oral presentations support potential of ensifentrine,an investigational, first-in-class, selective [Read more]